"There's no denial that AI has had a big impact on all scientific fields, including drug repurposing."

#RExPO25 highlights with Markus List (@itisalist.bsky.social), Group Leader at @daisybio.de & Associate Professor at TUM.

Watch the full video for more insights ⤵️
youtu.be/iz7PisP_n08?...

At #RExPO25 we welcomed @alfonsovalencia.bsky.social from @bsc-cns.bsky.social as the Honorary Lecturer, where he highlighted how computing and AI can help to advance biomedicine, and also the potential challenges.

Watch the full video for more insights ⤵️
youtu.be/iz7PisP_n08?...

RExPO25: the fourth international conference on systems medicine, AI and drug repurposing.

For more highlights about this year's conference, visit the #RExPO25 compilation page 👉 repo4.eu/rexpo25/

You'll find a photo gallery, key info about the event, full list of speakers & topics, and access to the conference proceedings (via @scienceopen.bsky.social).

@scienceinnovation.ec.europa.eu

🎬 The official #RExPO25 recap video is now live!

Featuring exclusive insights from some of the experts who spoke at REPO4EU's 4th international conference on Systems Medicine, AI and Drug Repurposing 💊

📍 Barcelona @prbb.org, 24-26 September '25

youtu.be/iz7PisP_n08?...

#RExPO25 💊 3 days in 30 seconds!

A huge thanks to everyone who joined us in Barcelona for the 4th edition of our international conference on Systems Medicine, AI & Drug Repurposing.

Check all talks and posters abstracts via @scienceopen.bsky.social ⤵️
drugrepocentral.scienceopen.com/search#%7B%2...

✨ Congratulations to Faren, the winner of the Young Investigator Award #RExPO25! This is a truly well-deserved recognition of her outstanding research and impact. 👏 @repo4eu.bsky.social

RANKOR: A Machine Learning Model for Drug Repurposing on Individual-Level Single Cell Data <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d26947238e95">Precision oncology aspires to align cancer patients with therapies that most effectively ...

Nice poster at @repo4eu.bsky.social #RExPO25 by Nikoletta Katsaouni 'RANKOR: A Machine Learning Model for Drug Repurposing on Individual-Level Single Cell Data' on @scienceopen.bsky.social : drugrepocentral.scienceopen.com/hosted-docum...

A New UI for AI-Driven Drug Repurposing in Rare Genetic Diseases: Real-World Impact from the NCATS Translator Program <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d90562e89">The NIH NCATS Translator program now exposes <b>&gt; 200 million semantically...

We are proud at @scienceopen.bsky.social to collaborate with the Hugh Kaul #PrecisionMedicine Inst in Alabama: 'A New UI for AI-Driven Drug Repurposing in Rare Genetic Diseases: Real-World Impact from the NCATS Translator Program' #RExPO25: drugrepocentral.scienceopen.com/hosted-docum...

Inference of Gene Regulatory Networks for Drug Repurposing: A CLR-Based Strategy to Predict Transcriptional Drug Effects <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d9292592e148">Drug repurposing provides a cost-effective approach to identifying new therapeutic indic...

Kicking off Day 3 of #RExPO25 - Stefano Piotto of SoftMining: 'Inference of Gene Regulatory Networks for Drug Repurposing: A CLR-Based Strategy to Predict Transcriptional Drug Effects' @repo4eu.bsky.social @scienceopen.bsky.social : drugrepocentral.scienceopen.com/hosted-docum...

RePo-SUDOE: A Transnational Network for Drug Repurposing in the SUDOE Space <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d13493990e380">The development of new drugs is hindered by high failure rates, substantial costs, and ...

At #RExPO25 and want to learn more about the RePo- SUDOE project? Check out the article in the journal Drug Repurposing: 'RePo-SUDOE: A Transnational Network for Drug Repurposing in the SUDOE Space' @repo4eu.bsky.social @scienceopen.bsky.social : drugrepocentral.scienceopen.com/hosted-docum...

👥 REMEDi4ALL joined our sister project REPO4EU at #RExPO25 in Barcelona for a programme on innovation in drug repurposing & systems medicine.

Read highlights from our session: patient engagement, training, new tools & collaboration 👉 https://loom.ly/k4uER7w

From Literature to Knowledge Graphs to Drug Repurposing <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d392105e255">Network-based drug repurposing requires the seamless synthesis of knowledge from both the...

New research at #RExPO25 Fernando Miguel Delgado-Chaves: 'From Literature to Knowledge Graphs to Drug Repurposing' @repo4eu.bsky.social : drugrepocentral.scienceopen.com/hosted-docum...

Drugst.One DREAM - Drug Repurposing through Expert Annotation and Modification <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d814479e258">Complex diseases often lack an actionable understanding of their underlying causal biolog...

One of the cool tools being developed as part of @repo4eu.bsky.social 'Drugst.One DREAM - Drug Repurposing through Expert Annotation and Modification' presented by Lisa Spindler at #RExPO25: Read on @scienceopen.bsky.social drugrepocentral.scienceopen.com/hosted-docum...

From Hype to Health Check: Critical Evaluation of Drug Response Prediction Models with DrEval <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d1367117e186">Large-scale drug sensitivity screens have enabled training drug response prediction mode...

Day 2 of #RExPO25 kicks off with a talk from Markus List of TU Munich: 'From Hype to Health Check: Critical Evaluation of Drug Response Prediction Models with DrEval' @repo4eu.bsky.social @scienceopen.bsky.social : drugrepocentral.scienceopen.com/hosted-docum...

✈️ The #AUSTRALOteam is on the move! While Diana and Alexandra are in Barcelona participating in #RExPO25, Mona and Laura are in Vicenza at the #GrapheneWeek2025. From Spain to Italy, our team is connecting with innovators, exchanging knowledge, and bringing fresh inspiration back to AUSTRALO.

🌍 #RExPO25 kicks off in Barcelona!

On #ScienceOpen, explore two diamond OA journals from Drug Repurposing Central:
🔬 Drug Repurposing – Vol. 2, Issue 1 now live ✨
🌐 Network & Systems Medicine – relaunch issue out now! 🆕

Comprehensive Network Medicine-Based Drug Repositioning via Integration of Therapeutic Efficacy and Side Effects <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d26893407e114">Despite advances in modern medicine that led to improvements in cardiovascular outcomes, ...

At #RExPO25, Paola Paci, editor for the journal "Network and Systems Medicine" speaks on 'Comprehensive Network Medicine-Based Drug Repositioning via Integration of Therapeutic Efficacy and Side Effects' Read the abstract @repo4eu.bsky.social drugrepocentral.scienceopen.com/hosted-docum...

An EATRIS delegation is at #RExPO25 in Barcelona, sharing outcomes from the #REMEDi4ALL project we coordinate – from patient engagement and training to our new partnering portal and global collaborations in #DrugRepurposing.

How can patient-based evidence support health technology assessment in mechanism-based drug repurposing? <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d2881e105"> <b>Background:</b> Health Technology Assessment (HTA) is a multi...

Up now at @repo4eu.bsky.social #RExPO25: Merel Kimmen 'How can patient-based evidence support health technology assessment in mechanism-based drug repurposing? ' Read the abstract on #ScienceOpen @scienceopen.bsky.social : drugrepocentral.scienceopen.com/hosted-docum...

🌍 REMEDi4ALL is LIVE at #RExPO25 in Barcelona!

Today we’re at Barcelona Biomedical Research Park for REPO4EU's annual conference, joining the community and taking the stage to discuss patient engagement, training, internationalisation and the REMEDi4ALL platform!

VRG‑145: A Synergistic Drug Repurposing Strategy for Enhanced Migraine Prophylaxis <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d1880278e181">Migraine prophylaxis remains an area of substantial unmet medical need. Current therapies ...

New therapies for migranes presented by Sándor Farkas at #RExPO25 'VRG‑145: A Synergistic Drug Repurposing Strategy for Enhanced #Migraine Prophylaxis'. Important work! @repo4eu.bsky.social @scienceopen.bsky.social : drugrepocentral.scienceopen.com/hosted-docum...

The Business Case for Drug Repurposing in Cri du Chat Syndrome Patients <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d13555163e151">Cri du Chat syndrome (CdCS) is a rare genetic disorder caused by spontaneous deletion o...

Inspiring! This talk by Karen Malone of Sherwood Pharmaceuticals at #RExPO25 showed the power of patient groups: 'The Business Case for Drug Repurposing in Cri du Chat Syndrome Patients': @repo4eu.bsky.social @scienceopen.bsky.social drugrepocentral.scienceopen.com/hosted-docum...

An Integrative Systems Medicine Framework for Ischemic Stroke: In Silico-Based Target Identification, Network Pharmacology, and Immune Mechanistic Redefinition <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d276929e183">Despite decades of translational research, translational stroke research has yield to no ...

Important work by Ana Casas at #RExPO25 'An Integrative Systems Medicine Framework for Ischemic #Stroke: In Silico-Based Target Identification, Network Pharmacology, and Immune Mechanistic Redefinition' @scienceopen.bsky.social @repo4eu.bsky.social : drugrepocentral.scienceopen.com/hosted-docum...

Great poster by Christian Gratz of @tumunich.bsky.social at #RExPO25 'Transcriptomic Biomarker Discovery from Extracellular Vesicles: A Workflow Using Off-Label Treatment of Anaplastic Thyroid #Cancer' @repo4eu.bsky.social @scienceopen.bsky.social : drugrepocentral.scienceopen.com/hosted-docum...

More #cancer research at #RExPO25! 'Drug repurposing for cancer and beyond through the RePo-SUDOE project' @repo4eu.bsky.social @scienceopen.bsky.social : drugrepocentral.scienceopen.com/hosted-docum...

Patient-derived lymphoma organoids and repurposed drugs: novel solutions for improved B cell lymphoma treatment <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d816596e219">B cell lymphomas (BCL) are a heterogenous group of hematologic malignancies, with over 70 identified subtypes. Current first line treatment for all subtypes is rituximab and chemotherapy regimen (R-CHOP); of the treated patients, up to 40-60% relapse or have refractory disease, with typically higher mortality rates. Therefore, more efficient treatment, but also improved <i>ex vivo</i> research models are needed to study the treatment response and resistance. To overcome the expensive and time-consuming process of drug discovery and development, we aim to combat the lymphoma heterogeneity with repurposed drugs, especially focusing on cationic amphiphilic drugs (CADs) that damage cancer cell lysosomes. </p><p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d816596e224">Lysosomes are central organelles in nutrient sensing and cellular metabolism. Malignant transformation rewires cellular metabolism to boost growth. In turn, cancer cells increase lysosomal production and activity to meet the metabolic needs. Our current results indicate that targeting the reported cancer cell lysosomal ‘weakness’ with repurposed CADs Ebastine and Penfluridol prevents pro-survival cell signaling, and suppresses long-term tumor outgrowth in B lymphoma cell lines, patient blood B cells, and in patient lymph node-derived organoids. </p><p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" dir="auto" id="d816596e226">We have developed a novel patient-derived lymphoma organoid model as an <i>ex vivo</i> drug assay platform from patients’ own cancer tissue. With combining the lymphoma organoid model and repurposed drugs, this study provides a simpler and cost-effective, yet translationally relevant clinical solution for personalized medicine and improved treatment of BCL patients. </p>

Another great talk at #RExPO25. Giving hope to #cancer patients. 'Patient-derived lymphoma organoids and repurposed drugs: novel solutions for improved B cell lymphoma treatment': drugrepocentral.scienceopen.com/hosted-docum...

Leveraging Cancer Drug Metabolites for Precision Drug Repurposing <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d26971189e181">Precision oncology benefits only a subset of patients, with approved drugs targeting le...

Really interesting talk by @albertantolin.bsky.social of
@idibell.bsky.social at #RExPO25. Patents underway! 'Leveraging #Cancer Drug Metabolites for Precision Drug Repurposing' @scienceopen.bsky.social @repo4eu.bsky.social : drugrepocentral.scienceopen.com/hosted-docum...

Repurposing Drugs through Network Pharmacology in Advanced Thyroid Cancer: From Bench to Bedside <p xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="first" dir="auto" id="d446414e216">Advanced thyroid cancer patients have limited treatment options and rarely result in a cu...

Great talk this morning at #RExPO25 by Prashant Changoer of @radboudumc.bsky.social 'Repurposing Drugs through Network Pharmacology in Advanced Thyroid #Cancer: From Bench to Bedside' @scienceopen.bsky.social @repo4eu.bsky.social : drugrepocentral.scienceopen.com/hosted-docum...
()

Great talks at #RExPO25 this morning. Really gives hope we can beat some of these cancers.

RExPO25 Honorary Lecturer: Alfonso Valencia, Barcelona Supercomputing Center (BSC). Title: Advancing biomedicine through computing, networks and AI - opportunities and challenges.

Meet the #RExPO25 Honorary Lecturer 💊 Alfonso Valencia (@bsc-cns.bsky.social)

We're honoured to welcome @alfonsovalencia.bsky.social to this year's conference! In his lecture, he'll reflect on advancing #Biomedicine through computing, networks & AI.

Check the full agenda ➡️ repo4.eu/rexpo25/agen...